AKAM
64
2
MRK
66
2
CHD
34
2
QCOM
46
2
PHM
52
-7
EQR
50
-3
CVX
34
5
NRG
59
5
PH
78
3
PSA
56
5
ZION
61
4
STT
67
2
BMY
69
6
VZ
54
2
DE
48
5
CFG
89
4
APD
55
3
URI
50
7
LUV
71
10
CTSH
63
3
AKAM
64
2
MRK
66
2
CHD
34
2
QCOM
46
2
PHM
52
-7
EQR
50
-3
CVX
34
5
NRG
59
5
PH
78
3
PSA
56
5
ZION
61
4
STT
67
2
BMY
69
6
VZ
54
2
DE
48
5
CFG
89
4
APD
55
3
URI
50
7
LUV
71
10
CTSH
63
3
Financhill
Back

CRISPR Therapeutics AG Stock Predictions

This AI Layer Just Raised Its Share Price

DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi
Sell
43

CRSP
CRISPR Therapeutics AG

Last Price:
$58.19
Seasonality Move:
11.08%

7 Day Trial

ALL ACCESS PASS

$ 7

$0.85 Entry Open - Fortune 1000 AI Tech in Demand

DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi

CRISPR Therapeutics AG Stock Forecast

  • Over the next 52 weeks, CRISPR Therapeutics AG has on average historically risen by 23.5% based on the past 9 years of stock performance.
  • CRISPR Therapeutics AG has risen higher in 6 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 66.67%
  • Is CRISPR Therapeutics AG Stock Undervalued?
    The current CRISPR Therapeutics AG [CRSP] share price is $55.99. The Score for CRSP is 43, which is 14% below its historic median score of 50, and infers higher risk than normal.
  • CRSP is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.

Will CRISPR Therapeutics AG Stock Go Up Next Year?

  • Over the next 52 weeks, CRISPR Therapeutics AG has on average historically risen by 23.5% based on the past 9 years of stock performance.

CRISPR Therapeutics AG Stock Rating

Sell
43
CRISPR Therapeutics AG (CRSP) is a Sell

Is CRISPR Therapeutics AG overpriced?

  • CRISPR Therapeutics AG has risen higher in 6 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 66.67%

CRISPR Therapeutics AG Stock Price History

Is CRSP stock going to rise?

  • Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and CRSP is experiencing buying pressure, which is a positive indicator for future bullish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
Switzerland
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
crisprtx.com

52-Week Data

52-Week High:
78.48
52-Week Low:
30.04

Prediction Charts

Market Cap:
5.3B
Price in USD:
55.99
Volume:
1.9M
Beta:
2.05

Technical Analysis

SMA50:
61.59
SMA100:
59.51
SMA200:
50.50
52-Wk Change:
9.27%

Stock Predictions

  • Is CRISPR Therapeutics AG stock public?
    Yes, CRISPR Therapeutics AG is a publicly traded company.
  • What is the CRISPR Therapeutics AG stock quote today?
    The CRISPR Therapeutics AG stock price is 55.99 USD today.
  • How to buy CRISPR Therapeutics AG stock online?
    You can buy CRISPR Therapeutics AG shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Nov-13 51.70 51.11 51.78 50.27
Nov-14 49.58 52.53 54.77 49.11
Nov-17 51.36 55.32 55.77 51.22
Nov-18 54.69 53.47 54.99 52.07
Nov-19 53.83 50.73 53.83 50.56
Nov-20 51.61 49.29 53.20 48.24
Nov-21 48.48 50.23 51.45 48.02
Nov-24 50.40 51.25 51.51 49.31
Nov-25 50.89 53.57 53.89 49.96
Nov-26 53.63 53.30 53.78 52.30
Nov-28 52.84 53.47 54.00 51.50
Dec-1 52.30 52.17 53.46 51.00
Dec-2 52.43 51.58 53.03 51.20
Dec-3 51.49 55.99 56.01 51.16

CRISPR Therapeutics AG Earnings

CRISPR Therapeutics AG Earnings Report: Per Share CRISPR Therapeutics AG Earnings Q1 Q2 Q3 and Q4 last year and next year.

CRISPR Therapeutics AG Forecast Revenue Growth

CRISPR Therapeutics AG Stock Analysis: Historical quarterly revenues per share for CRISPR Therapeutics AG and historical quarterly revenue growth:

  • Analysts estimate an earnings decrease this quarter of $0.26 per share, a decrease next quarter of $0.00 per share, a decrease this year of $1.09 per share, and an increase next year of $1.74 per share.

* CRISPR Therapeutics AG stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.